Allay Tx is developing a drug-eluting biopolymer for sustained post-operative orthopedic pain management.
allaytx.com
Menlo Park, CA
CEO: Adam Gridley
Arboretum lead: Paul McCreadie
Allay Therapeutics
IN THE NEWS
Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the results from a Phase 2B clinical study of its lead…
Read More
Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical
Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s…
Read More
